MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. (Q53122691)

11 May 2018

title

MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. (English)

1 reference

11 May 2018

author name string

Young-Ae Kim

1

1 reference

11 May 2018

Hee Jin Lee

2

1 reference

11 May 2018

Sun-Hee Heo

3

1 reference

11 May 2018

Hye Seon Park

4

1 reference

11 May 2018

Suk Young Park

5

1 reference

11 May 2018

WonSeon Bang

6

1 reference

11 May 2018

In Hye Song

7

1 reference

11 May 2018

In Ah Park

8

1 reference

11 May 2018

Gyungyub Gong

9

1 reference

11 May 2018

language of work or name

English

0 references

publication date

13 April 2016

1 reference

11 May 2018

Breast Cancer Research and Treatment

published in

1 reference

11 May 2018

volume

156

1 reference

11 May 2018

page(s)

597-606

1 reference

11 May 2018

issue

3

1 reference

11 May 2018

https://scigraph.springernature.com/pub.10.1007/s10549-016-3786-z

exact match

0 references

cites work

Androgen receptor in triple negative breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Immunotherapeutic options on the horizon in breast cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Genetic alterations and oncogenic pathways associated with breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Therapies for triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Structural analysis of tumor-related single amino acid mutations in human MxA protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Mx GTPases: dynamin-like antiviral machines of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Type 1 interferons and antiviral CD8 T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Functional diversity of Mx proteins: variations on a theme of host resistance to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3786-Z

10.1007/S10549-016-3786-Z

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

27075916

1 reference

11 May 2018